2019
Prevalence of False-Negative Results of Intraoperative Consultation on Surgical Margins During Resection of Gastric and Gastroesophageal Adenocarcinoma
McAuliffe JC, Tang LH, Kamrani K, Olino K, Klimstra DS, Brennan MF, Coit DG. Prevalence of False-Negative Results of Intraoperative Consultation on Surgical Margins During Resection of Gastric and Gastroesophageal Adenocarcinoma. JAMA Surgery 2019, 154: 126-132. PMID: 30422226, PMCID: PMC6439656, DOI: 10.1001/jamasurg.2018.3863.Peer-Reviewed Original ResearchConceptsCurative-intent resectionSurgical marginsIOC resultsGastroesophageal adenocarcinomaNeoadjuvant radiotherapyIntraoperative consultationFN resultsClinical implicationsDuodenal marginsFalse-negative resultsSingle institution referral centerResection of gastricDisease-specific survivalStage of diseaseTrue-positive resultsGastric marginSurgical fitnessCurative intentReferral centerSubsequent resectionEsophageal resectionRetrospective studyGastrointestinal pathologistsDiffuse diseaseTumor location
2011
Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent
Mayo SC, Nathan H, Cameron JL, Olino K, Edil BH, Herman JM, Hirose K, Schulick RD, Choti MA, Wolfgang CL, Pawlik TM. Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent. Cancer 2011, 118: 2674-2681. PMID: 21935914, PMCID: PMC3578343, DOI: 10.1002/cncr.26553.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaConditional survivalConditional survival estimatesActuarial survivalCurative intentPositive marginsSurvival estimatesDuctal adenocarcinomaResection of PDACPostoperative year 5Date of surgeryCox regression analysisPredictors of survivalTime of surgeryMedian survivalMargin statusWorse survivalHigher lymphKaplan-MeierTumor sizeLarge cohortPatientsMultivariate analysisLymphSurgery
2010
Clinicopathologic Analysis of Ampullary Neoplasms in 450 Patients: Implications for Surgical Strategy and Long-Term Prognosis
Winter JM, Cameron JL, Olino K, Herman JM, de Jong MC, Hruban RH, Wolfgang CL, Eckhauser F, Edil BH, Choti MA, Schulick RD, Pawlik TM. Clinicopathologic Analysis of Ampullary Neoplasms in 450 Patients: Implications for Surgical Strategy and Long-Term Prognosis. Journal Of Gastrointestinal Surgery 2010, 14: 379-387. PMID: 19911239, DOI: 10.1007/s11605-009-1080-7.Peer-Reviewed Original ResearchConceptsLymph node metastasisAmpullary neoplasmsNode metastasisSurgical resectionTumor sizeInvasive adenocarcinomaMicroscopic vessel invasionInitial surgical procedureMedian tumor sizeOutcomes of patientsPoor histologic gradeLong-term prognosisSingle-institution databaseRegional lymph nodesAmpulla of VaterEarly invasive adenocarcinomaDepth of invasionMethodsBetween 1970Metastatic diseaseRadical resectionAmpullary adenomasClinicopathologic factorsLymph nodesClinicopathologic analysisPerineural invasion
2009
SMAD4 Gene Mutations Are Associated with Poor Prognosis in Pancreatic Cancer
Blackford A, Serrano OK, Wolfgang CL, Parmigiani G, Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Eshleman JR, Goggins M, Jaffee EM, Iacobuzio-Donahue CA, Maitra A, Cameron JL, Olino K, Schulick R, Winter J, Herman JM, Laheru D, Klein AP, Vogelstein B, Kinzler KW, Velculescu VE, Hruban RH. SMAD4 Gene Mutations Are Associated with Poor Prognosis in Pancreatic Cancer. Clinical Cancer Research 2009, 15: 4674-4679. PMID: 19584151, PMCID: PMC2819274, DOI: 10.1158/1078-0432.ccr-09-0227.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overFemaleGene DeletionHumansKaplan-Meier EstimateMaleMiddle AgedMutationPancreatic NeoplasmsPrognosisProtein Serine-Threonine KinasesReceptor, Transforming Growth Factor-beta Type IIReceptors, Transforming Growth Factor betaSmad4 ProteinTumor Suppressor Protein p53ConceptsPoor prognosisPancreatic cancerLymph node statusShorter overall survivalSMAD4 gene mutationUnderwent pancreaticoduodenectomyOverall survivalMargin statusNode statusTumor sizePatient outcomesPatientsAdenocarcinomaPancreasCancerPrognosisGene mutationsSMAD4 inactivationGene inactivationSomatic mutationsHomozygous deletionMonthsSurvival